1
|
Akpabio A, Adebajo A. Evaluating upadacitinib for the treatment of psoriatic arthritis. Expert Opin Pharmacother 2022; 23:169-173. [PMID: 35014922 DOI: 10.1080/14656566.2021.2006183] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
INTRODUCTION Psoriatic arthritis is an extra-cutaneous manifestation affecting up to 40% of psoriasis patients with multiple therapies recommended by international guidelines including conventional and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) as well as biologics. Janus kinase inhibitors (JAKis) have emerged as a unique therapeutic target with tofacitinib the first to gain FDA approval in 2017. The non-selectivity of older JAKis increases the risk of off-target effects such as suppression of hemopoiesis hence the rationale for more selective alternatives. AREAS COVERED This paper explores the use of upadacitinib (a selective JAK1 inhibitor) for the treatment of psoriatic arthritis. It covers its chemical properties, pharmacokinetics, pharmacodynamics, efficacy, safety and regulation. EXPERT OPINION In our opinion, upadacitinib is set to play an important role in the treatment of psoriatic arthritis as demonstrated by the SELECT-PsA trials especially in patients with poor or non-response to current first-line therapies. It's JAK1 receptor selectivity promises a lower side effect profile compared to the older nonselective JAKis but this will require confirmation with long-term clinical trial data.
Collapse
Affiliation(s)
- Akpabio Akpabio
- Rheumatology Department, Royal Hallamshire Hospital, Sheffield, UK
| | - Adewale Adebajo
- Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK
| |
Collapse
|
2
|
Köhm M, Burkhardt H, Behrens F. Therapiestrategien der Psoriasisarthritis. AKTUELLE DERMATOLOGIE 2021. [DOI: 10.1055/a-1676-9290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Zusammenfassung
Bestehende Therapieempfehlungen und deren Limitationen In den letzten Jahren haben sich die Basistherapieoptionen für die Behandlung der Psoriasisarthritis deutlich erweitert. Das Sicherheitsprofil der verfügbaren Therapien ist gut untersucht und für die verschiedenen Präparate bekannt. Verschiedene Empfehlungen zur Auswahl und Steuerung der geeigneten Therapie stehen dem Behandler zur Verfügung. Hierbei finden die Empfehlungen der European League Against Rheumatism (EULAR) und der Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) national und international in der Routine Anwendung.
Zugelassene Therapieoptionen zur Behandlung der Psoriasisarthritis csDMARD-Therapien haben im Vergleich zur RA in der PsA-Behandlung eine schlechte Evidenzlage. Für neue Substanzen in den Kategorien tsDMARD und bDMARD liegen höhere Evidenzniveaus vor. Da neue Therapien unterschiedliche Zielstrukturen adressieren, bieten sich zunehmend Chancen der personalisierten und individualisierten Therapieentscheidung. Gerade neue pathophysiologische Erkenntnisse zum Erkrankungsbild und die daraus resultierenden Therapieoptionen, die gezielt spezifische Targets adressieren, bieten Möglichkeiten einer immer differenzierteren und individualisierten medikamentösen Behandlung zur Verbesserung der Versorgung der PsA-Patienten, v. a. mit Fokus auf personalisierte Strategien zur optimalen Behandlung verschiedener Manifestationsformen und -muster.
Randomisierte kontrollierte Studien und deren Relevanz für den Versorgungsalltag Studienendpunkte randomisierter kontrollierter Studien, deren Studiendesign oft aus der rheumatoiden Arthritis entliehen ist, dienen auch aufgrund der großen Heterogenität der Erkrankung kaum als Basis für individuelle Therapieentscheidungen. Ein mehrschrittiges Vorgehen bei der Auswahl eines individualisierten Behandlungsregimes ist wichtig unter Berücksichtigung der klinischen Manifestation, potenzieller Begleiterkrankungen, von Langzeitsicherheitsaspekten, Kontraindikationen, Applikationsformen und nicht zuletzt des Patientenwunschs.
Collapse
Affiliation(s)
- Michaela Köhm
- Abteilung Rheumatologie, Goethe-Universität Frankfurt/Main
- Fraunhofer-IME, Institutsteil Translationale Medizin und Pharmakologie (TMP), Frankfurt/Main
- Fraunhofer-Exzellenzcluster für immunmediierte Erkrankungen CIMD
| | - Harald Burkhardt
- Abteilung Rheumatologie, Goethe-Universität Frankfurt/Main
- Fraunhofer-IME, Institutsteil Translationale Medizin und Pharmakologie (TMP), Frankfurt/Main
- Fraunhofer-Exzellenzcluster für immunmediierte Erkrankungen CIMD
| | - Frank Behrens
- Abteilung Rheumatologie, Goethe-Universität Frankfurt/Main
- Fraunhofer-IME, Institutsteil Translationale Medizin und Pharmakologie (TMP), Frankfurt/Main
- Fraunhofer-Exzellenzcluster für immunmediierte Erkrankungen CIMD
| |
Collapse
|
3
|
Iizuka Y, Takase-Minegishi K, Hirahara L, Kirino Y, Soejima Y, Namkoong H, Horita N, Yoshimi R, Takeuchi M, Takeno M, Mizuki N, Nakajima H. Beneficial Effects of Apremilast on Genital Ulcers, Skin Lesions, and Arthritis in Patients With Behçet's Disease: A Systematic Review and Meta-Analysis. Mod Rheumatol 2021; 32:1153-1162. [PMID: 34752620 DOI: 10.1093/mr/roab098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Revised: 10/15/2021] [Accepted: 10/21/2021] [Indexed: 11/13/2022]
Abstract
OBJECTIVE This study aimed to determine the clinical efficacy of apremilast for oral ulcers, extra-oral manifestations, and overall disease activity in patients with Behçet's disease (BD). METHODS A systematic literature search was performed in PubMed, EMBASE, Cochrane Library, and Web of Science Core Collection. Studies assessing the treatment effects of apremilast in BD were included. The odds ratios (ORs) of being symptom free for individual manifestations and mean difference (MD) of Behçet's Disease Current Activity Form (BDCAF) scores were calculated with 95% confidence intervals (CIs) at 12 and 24 weeks using a random-model meta-analysis. RESULTS Of 259 screened articles, eight were included. After 12 weeks of apremilast treatment the OR of symptom-free was as followings: oral ulcers, 45.76 (95% CI, 13.23-158.31); genital ulcers, 4.56 (95% CI, 2.47-8.44); erythema nodosum, 3.59 (95% CI, 1.11-11.61); pseudofolliculitis, 2.81 (95% CI, 1.29-6.15); and arthritis, 3.55 (95% CI, 1.71-7.40). Furthermore, BDCAF scores at 12 weeks were significantly reduced (MD=-1.38; -1.78 to -0.99). However, the proportion of oral-ulcer free patients increased at 24 weeks (OR=14.88; 4.81 to 46.07). CONCLUSION The currently accumulated data indicates an improvement in mucocutaneous and articular symptoms by short-term apremilast treatment in patients with BD.
Collapse
Affiliation(s)
- Yuki Iizuka
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Kaoru Takase-Minegishi
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Lisa Hirahara
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Yohei Kirino
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Yutaro Soejima
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Ho Namkoong
- Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
| | - Nobuyuki Horita
- Chemotherapy Center, Yokohama City University Hospital, Yokohama, Japan
| | - Ryusuke Yoshimi
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Masaki Takeuchi
- Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Mitsuhiro Takeno
- Department of Allergy and Rheumatology, Nippon Medical School Musashi Kosugi Hospital, Kawasaki, Japan
| | - Nobuhisa Mizuki
- Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Hideaki Nakajima
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| |
Collapse
|
4
|
Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, Chou RC, Mendelsohn AM, Rozzo SJ, Gottlieb A. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis 2021; 80:1147-1157. [PMID: 33985942 PMCID: PMC8372392 DOI: 10.1136/annrheumdis-2020-219014] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 01/29/2021] [Accepted: 02/01/2021] [Indexed: 12/13/2022]
Abstract
Objectives To evaluate efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tildrakizumab in patients with psoriatic arthritis (PsA). Methods In this randomised, double-blind, placebo-controlled, phase IIb study, patients with active PsA were randomised 1:1:1:1:1 to tildrakizumab 200 mg every 4 weeks (Q4W); tildrakizumab 200, 100 or 20 mg Q12W; or placebo Q4W. Patients receiving tildrakizumab 20 mg or placebo switched to tildrakizumab 200 mg Q12W at W24; treatment continued to W52. The primary efficacy endpoint was proportion of patients with ACR20 response (≥20% improvement by American College of Rheumatology criteria) at W24. Secondary efficacy endpoints were assessed without adjustment for multiplicity. Safety was evaluated from treatment-emergent adverse events (TEAEs). Results 391/500 patients screened were randomised and treated. At W24, 71.4%–79.5% of tildrakizumab-treated versus 50.6% of placebo-treated patients achieved ACR20 (all p<0.01). Patients receiving tildrakizumab versus placebo generally achieved higher rates of ACR50, Disease Activity Score in 28 joints with C reactive protein <3.2, minimal disease activity and 75%/90%/100% improvement from baseline Psoriasis Area and Severity Index responses at W24 and through W52. Improvement in dactylitis and enthesitis was not observed; results were mixed for other outcomes. Responses in patients switched to tildrakizumab 200 mg at W24 were consistent with treatment from baseline. TEAEs and serious TEAEs occurred in 64.5% and 3.3%, respectively, of all patients through W52 and were comparable among treatment arms. Conclusions Tildrakizumab treatment significantly improved joint and skin manifestations of PsA other than dactylitis and enthesitis. Treatment was generally well tolerated through W52. Clinicaltrials.gov NCT02980692.
Collapse
Affiliation(s)
- Philip J Mease
- Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA .,Providence St. Joseph Health and University of Washington, Seattle, Washington, USA
| | - Saima Chohan
- Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, Arizona, USA
| | | | - Michael E Luggen
- Cincinnati Rheumatic Disease Study Group, Cincinnati, Ohio, USA.,Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
| | - Proton Rahman
- Medicine, Eastern Health and Memorial University, St. Johns, Newfoundland, Canada
| | - Siba P Raychaudhuri
- Division of Rheumatology, Allergy and Clinical Immunology, University of California School of Medicine, Davis, California, USA.,Rheumatology, VA Medical Center Sacramento, Sacramento, California, USA
| | - Richard C Chou
- Division of Allergy, Immunology and Rheumatology, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York, USA
| | | | | | - Alice Gottlieb
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| |
Collapse
|
5
|
Abstract
Axial involvement in psoriatic arthritis is a well-recognized manifestation with a prevalence between 12.5% and 78%. This huge heterogeneity is due to the different criteria used by authors to define psoriatic arthritis with axial involvement combining clinical features with radiographic evidence of disease. Specific genetic and clinical attributes of axial psoriatic arthritis might differentiate it from axial spondyloarthritis with concurrent skin psoriasis. Few studies address the specific management. The purpose of this review is to acknowledge the current understanding of axial involvement in psoriatic arthritis and highlight the need for a definition to facilitate research and clinical recognition.
Collapse
|
6
|
Zhukov AS, Khairutdinov VR, Samtsov AV. Precision therapy for psoriasis patients. VESTNIK DERMATOLOGII I VENEROLOGII 2020. [DOI: 10.25208/0042-4609-2019-95-6-14-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Affiliation(s)
- A. S. Zhukov
- S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation
| | - V. R. Khairutdinov
- S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation
| | - A. V. Samtsov
- S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation
| |
Collapse
|
7
|
Affiliation(s)
- Mitsuhiro Takeno
- Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
8
|
Abstract
Psoriatic arthritis (PsA) is a very heterogeneous immune-mediated disease that usually involves skin and joints but can also affect entheses and extra-articular structures during the disease course. Furthermore, it can also be linked with other associated diseases. Therefore, the individualized selection of an effective and patient-oriented treatment must be carried out taking the extent of various manifestations of the PsA itself and also of other influencing factors into consideration. Various recommendations for selection and control of the suitable treatment of PsA are available for clinical use. The recommendations of the European League Against Rheumatism (EULAR) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) are the two recommendations that are frequently used and internationally acknowledged. Both recommendations were updated in 2016. Specific German treatment recommendations are currently missing. In analogy to the treat-to-target strategy for rheumatoid arthritis, at least minimal disease activity (MDA) should be achieved in PsA patients with the use of specific therapeutic interventions if remission as the maximum therapeutic goal cannot be reached. New treatment options, which target different specific molecules, offer possibilities for a more differentiated personalized medicinal treatment for improvement of the care of PsA patients. This particularly applies to a focus on personalized strategies for optimal treatment of various manifestation forms and patterns.
Collapse
Affiliation(s)
- M Köhm
- Abteilung Rheumatologie, Goethe-Universität Frankfurt/Main, Theodor-Stern-Kai 7, 60596, Frankfurt/Main, Deutschland
- Institutsteil Translationale Medizin und Pharmakologie (TMP), Fraunhofer IME, Frankfurt/Main, Deutschland
| | - F Behrens
- Abteilung Rheumatologie, Goethe-Universität Frankfurt/Main, Theodor-Stern-Kai 7, 60596, Frankfurt/Main, Deutschland.
- Institutsteil Translationale Medizin und Pharmakologie (TMP), Fraunhofer IME, Frankfurt/Main, Deutschland.
| |
Collapse
|
9
|
Bakulev AL, Samtsov AV, Kubanov AA, Khairutdinov VR, Kokhan MM, Artemyeva AV, Derbin SI, Chernyaeva EV, Ivanov RA. Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext. VESTNIK DERMATOLOGII I VENEROLOGII 2019. [DOI: 10.25208/0042-4609-2019-95-3-54-64] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Netakimabis original monoclonal antibody against IL-17. This article outlines the key results of a phase II open-label extension trial of netakimab 80 mg and 120 mg in patients with moderate-to-severe psoriasis.The main aim of the trial is to estimate efficacy, safety and immunogenicity of long-term treatment with netakimab 80 mg and 120 mg in patients with moderate-to-severe psoriasis.Materials and methods. The BCD-085-2-ext study is a comparative, open-label phase 2 clinical study of the effi - cacy and safety of netakimab in patients with moderate-to-severe plaque psoriasis who had finished BCD-085-2 (NCT02762994) trial. Main efficacy endpoints includePASI75, PASI90, PASI100, sPGA = 0–1 on week 38 of the trial, long-term PASI75/90/100 retention, efficacy keeping after switch from once every 2 week regimen to once every 4 week regimen. Safety endpoints include adverse events, serious adverse events number and their profile.Results. 103 patients were included. PASI75 at week 38 was reached by 98.06 %, PASI90 — by 92.23 %, PASI100 — by 59.22 % of patients. There were no cases of serious adverse event, early with drawal due to adverse events and cases of grade 4 toxicity according to CTCAE 4.03. There were no cases of binding antibodies to netakimab during the 38 weeks of the study.Conclusion. The first Russian original IL-17 inhibitor netakimabis promising modern medicine for moderate-to-severe plaque psoriasis treatment. Netakimabshowed high efficacy, favorable safety profile and low immunogenicity during one year of the treatment.
Collapse
Affiliation(s)
- A. L. Bakulev
- Saratov State Medical Universit y named after V. I. Razumovsky, Ministr y of Health of the Russian Federation
| | - A. V. Samtsov
- S. M. Kirov Militar y Medical Academy, Ministr y of Defence of the Russian Federation
| | - A. A. Kubanov
- State Research Center of Dermatovenereology and Cosmetology, Ministr y of Health of the Russian Federation
| | - V. R. Khairutdinov
- S. M. Kirov Militar y Medical Academy, Ministr y of Defence of the Russian Federation
| | - M. M. Kokhan
- Ural Research Institute for Dermatovenerology and Immunopatology
| | | | | | | | | |
Collapse
|
10
|
Kubanov AA, Bakulev AL, Samtsov AV, Khairutdinov VR, Sokolovskiy EV, Kokhan MM, Artemyeva AV, Chernyaeva EV, Ivanov RA. Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis. VESTNIK DERMATOLOGII I VENEROLOGII 2019. [DOI: 10.25208/0042-4609-2019-95-2-15-28] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Abstract
Netakimab, the original monoclonal antibody against IL-17A, is an innovative drug for the treatment of moderate-to-severe plaque psoriasis in patients who have indications for systemic therapy or phototherapy. Netakimab was approved in Russian Federation, registration certificate number ЛП-005439 from 04.04.2019. This article outlines the first 12-week results of a phase III clinical trial in patients with psoriasis.Materials and methods. The BCD-085-7 study (PLANETA) is a comparative, randomized, double-blind, placebo-controlled phase 3 clinical study of the efficacy and safety of netakimab in patients with moderate-to-severe plaque psoriasis. This review presents the results of the first 12 weeks. The study is ongoing at the moment, the total duration of treatment for each patient is 3 years (154 weeks). Patients were randomized in a ratio of 2:2:1 into one of three arms: group 1 received netakimab subcutaneously at a dose of 120 mg once a week for the first three weeks (induction) and then once every 2 weeks up to week 10, group 2 received netakimab subcutaneously at a dose of 120 mg once a week for the first three weeks (induction) and then once every 4 weeks up to week 10, group 3 received a placebo subcutaneously on day 1 at weeks 0, 1, 2, 4, 6, 8 10. In order to maintain a double-blind design, placebo was administered to patients in group 2 at weeks 4 and 8.Results. Both netakimab groups showed a significant superiority over placebo (p < 0.001) and the absence of statistically significant differences between the two regimens of therapy (p > 0.05) across all endpoints. PASI 75 at week 12 was reached by 77.65 % of patients using netakimab once every 2 weeks and 83.33 % of patients using netakimab once every 4 weeks (ITT population). The rate of clear and almost clear skin (sPGA 0–1) was reached by 81.18 and 79.76 % of patients using netakimab once every 2 weeks and once every 4 weeks, respectively. The safety assessment showed no statistically significant differences between the groups, the incidence rate of adverse events in netakimab arms was not higher than in the placebo arm. There were no cases of early withdrawal due to adverse events and cases of grade 4 toxicity according to CTCAE 4.03. During the 12 weeks of the study, one serious adverse event was registered in group 2 (pneumonia grade 3), which was recovered without any consequences. The immunogenicity assessment showed binding antibodies formation at week 12 in one patient who received BCD-085 every 2 weeks. Neutralizing antibodies were not detected. Conclusion. Netakimab showed high efficacy in the treatment of psoriasis, more than 80 % of patients achieved PASI 75 and sPGA 0–1 (clear and almost clear skin) by the week 12 of treatment. The drug showed a favorable safety profile and low immunogenicity. Based on the study results the regimen once a week during the first 3 weeks (induction), then once every 4 weeks was chosen for medical use in patients with psoriasis.
Collapse
Affiliation(s)
- A. A. Kubanov
- State Research Center of Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation
| | - A. L. Bakulev
- Saratov State Medical University named after V. I. Razumovsky, Ministry of Health of the Russian Federation
| | - A. V. Samtsov
- S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation
| | - V. R. Khairutdinov
- S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation
| | - E. V. Sokolovskiy
- Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation
| | - M. M. Kokhan
- Ural Research Institute for Dermatovenerology and Immunopatology
| | | | | | | |
Collapse
|
11
|
Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol 2019; 14:719-730. [PMID: 30118353 DOI: 10.1080/1744666x.2018.1512404] [Citation(s) in RCA: 59] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
INTRODUCTION Psoriasis and psoriatic arthritis (PsA) are inflammatory immune-mediated conditions which can cause considerable disability and reduced quality of life. Management can be complex as clinical heterogeneity may lead to different treatment pathways. Tofacitinib is a novel, oral Janus Kinase (JAK) inhibitor with proven efficacy in rheumatoid arthritis. Areas covered: This review analyzes recent studies of tofacitinib in psoriatic disease treatment. The relevant literature was identified using clinicaltrials.gov, PubMed, and Google Scholar. Tofacitinib efficacy was demonstrated in PsA by the OPAL Broaden and OPAL Beyond phase-III studies, and received FDA and EMA approval. Tofacitinib was superior to placebo for the treatment of moderate-to-severe plaque psoriasis in the OPT Pivotal 1 and 2, OPT Retreatment studies, but FDA approval was declined for this indication based on issues of clinical efficacy and long-term safety. Expert commentary: Tofacitinib is an important oral drug for the treatment of PsA. However, the long-term safety data require further evaluation. Tofacitinib and other JAK inhibitors show potential to broaden the treatment options in PsA and other inflammatory conditions.
Collapse
Affiliation(s)
- Anna Berekmeri
- a Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM) , University of Leeds, NIHR Leeds Biomedical Research Centre (BRC) & Department of Dermatology, Leeds Teaching Hospitals , Leeds , UK
| | - Farrouq Mahmood
- b Rheumatology , Bradford Teaching Hospitals , Bradford , UK
| | - Miriam Wittmann
- a Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM) , University of Leeds, NIHR Leeds Biomedical Research Centre (BRC) & Department of Dermatology, Leeds Teaching Hospitals , Leeds , UK
| | - Philip Helliwell
- c Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM) , University of Leeds, Chapel Allerton Hospital , Leeds , UK
| |
Collapse
|
12
|
Alten R, Conaghan PG, Strand V, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl SM, Deodhar A. Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study. Clin Rheumatol 2019; 38:1615-1626. [DOI: 10.1007/s10067-019-04446-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Revised: 01/15/2019] [Accepted: 01/21/2019] [Indexed: 01/01/2023]
|
13
|
Tsuruta N, Narisawa Y, Imafuku S, Ito K, Yamaguchi K, Miyagi T, Takahashi K, Fukamatsu H, Morizane S, Koketsu H, Yamaguchi M, Hino R, Nakamura M, Ohyama B, Ohata C, Kuwashiro M, Sato T, Saito K, Kaneko S, Yonekura K, Hayashi H, Yanase T, Morimoto K, Sugita K, Yanagihara S, Kikuchi S, Mitoma C, Nakahara T, Furue M, Okazaki F. Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-α inhibitors. J Dermatol 2019; 46:193-198. [PMID: 30628100 DOI: 10.1111/1346-8138.14745] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Accepted: 11/16/2018] [Indexed: 11/29/2022]
Abstract
Psoriatic arthritis (PsA) is an inflammatory arthritis with as yet unclear pathophysiology. This retrospective, multicenter, cross-sectional study was conducted in 19 facilities in western Japan and aimed to identify patients' characteristics and factors that affect the results of treatment with biologic agents. Of 2116 patients with psoriasis, 285 (13.5%) had PsA. Skin manifestations preceded joint manifestations in 69.8%, the onset was simultaneous in 17.2%, whereas PsA preceded skin manifestations in 2.5%. Peripheral arthritis was most common, occurring in 73.7%, compared with axial disease in 21.8%, enthesitis in 23.5% and dactylitis in 35.4%. Patients with severe skin manifestations were significantly younger at onset (P = 0.02) and more frequently had axial disease (P < 0.01). Biologic agents were used in 206 patients (72.3%), anti-tumor necrosis factor (TNF)-α antibodies being prescribed first to 157 of them. Anti-TNF-α antibodies were continued by 105 participants and discontinued by 47, the remaining five patients being lost to follow up. Patients who discontinued anti-TNF-α antibodies were significantly older than those who continued (55 vs 51 years, P = 0.04) and significantly older at onset of joint manifestations (50 vs 44 years, P = 0.01). Multivariate analysis revealed that patients over 50 years significantly more frequently terminated anti-TNF-α antibodies (P < 0.01). In conclusion, patients with PsA and severe skin manifestations have earlier onset and axial disease, which seriously impacts on quality of life. Anti-TNF-α antibodies were generally effective enough to continue but less so in patients aged over 50 years. Further detailed research is needed.
Collapse
Affiliation(s)
- Noriko Tsuruta
- Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.,Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
| | - Yutaka Narisawa
- Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
| | - Shinichi Imafuku
- Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Kotaro Ito
- Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Kazuki Yamaguchi
- Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Takuya Miyagi
- Department of Dermatology, University of the Ryukyus, Graduate School of Medicine, Nishihara, Japan
| | - Kenzo Takahashi
- Department of Dermatology, University of the Ryukyus, Graduate School of Medicine, Nishihara, Japan
| | - Hiroko Fukamatsu
- Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Shin Morizane
- Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Hideki Koketsu
- Department of Dermatology, University of Miyazaki, Miyazaki, Japan
| | - Michiya Yamaguchi
- Department of Dermatology, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - Ryosuke Hino
- Hino Dermatology Clinic, Fukutsu, Japan.,Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Motonobu Nakamura
- Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Bungo Ohyama
- Department of Dermatology, Kurume University School of Medicine, Kurume, Japan
| | - Chika Ohata
- Department of Dermatology, Kurume University School of Medicine, Kurume, Japan
| | - Maki Kuwashiro
- Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
| | - Toshihiro Sato
- Iisora-Hifuka Clinic, Oita, Japan.,Department of Dermatology, Oita Prefectural Hospital, Oita, Japan
| | - Kanami Saito
- Department of Dermatology, Oita Prefectural Hospital, Oita, Japan
| | - Sakae Kaneko
- Department of Dermatology, Faculty of Medicine, Shimane University, Izumo, Japan
| | - Kentaro Yonekura
- Department of Dermatology, Imamura General Hospital, Kagoshima, Japan
| | - Hiroaki Hayashi
- Department of Dermatology, Kawasaki Medical School, Kawasaki, Japan
| | - Tetsuji Yanase
- Department of Dermatology, Onomichi General Hospital, Onomichi, Japan
| | - Kenichi Morimoto
- Division of Dermatology, Hiroshima Prefectural Hospital, Hiroshima, Japan
| | - Kazunari Sugita
- Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Shigeto Yanagihara
- Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Satoko Kikuchi
- Department of Dermatology, Kyushu Central Hospital, Fukuoka, Japan
| | - Chikage Mitoma
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Takeshi Nakahara
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Masutaka Furue
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Fusako Okazaki
- Department of Dermatology, Fukuyama City Hospital, Fukuyama, Japan
| |
Collapse
|
14
|
Coates LC, Rahman P, Psaradellis E, Rampakakis E, Osborne B, Lehman AJ, Nantel F. Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab. Rheumatology (Oxford) 2018; 58:522-526. [DOI: 10.1093/rheumatology/key359] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Accepted: 09/23/2018] [Indexed: 01/22/2023] Open
Affiliation(s)
- Laura C Coates
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
| | - Proton Rahman
- Faculty of Medicine, Memorial University, St Johns, NL, Canada
| | | | | | | | | | | |
Collapse
|
15
|
McInnes IB, Nash P, Ritchlin C, Choy EH, Kanters S, Thom H, Gandhi K, Pricop L, Jugl SM. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. J Comp Eff Res 2018; 7:1107-1123. [PMID: 30230361 DOI: 10.2217/cer-2018-0075] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
AIM A network meta-analysis using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (American College of Rheumatology [ACR], Psoriasis Area Severity Index [PASI] and Psoriatic Arthritis Response Criteria [PsARC] response rates) at 12-16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab, infliximab and ustekinumab. PATIENTS & METHODS Trials were identified by systematic review. Separate networks were developed for the full-study populations, biologic-naive patients and biologic-experienced patients. RESULTS In the full populations, secukinumab, adalimumab, golimumab and infliximab demonstrated the highest ACR response rates. Secukinumab and infliximab demonstrated the highest PASI response rates, and infliximab and etanercept demonstrated the highest PsARC response rates. CONCLUSION In the full populations, secukinumab demonstrated good efficacy across all outcomes. All treatments for active PsA included in this comprehensive network meta-analysis demonstrated superiority to placebo.
Collapse
Affiliation(s)
- Iain B McInnes
- University of Glasgow, Institute of Infection, Immunity & Inflammation, College of Medical, Veterinary & Life Sciences, University of Glasgow, Sir Graeme Davies Building, 120 University Place, Glasgow G12 8TA, UK
| | - Peter Nash
- Department of Medicine, University of Queensland, Brisbane, QLD 4072, Australia
| | - Christopher Ritchlin
- Division of Allergy, Immunology & Rheumatology, University of Rochester, 601 Elmwood Avenue, Box 695, Rochester, NY 1464, USA
| | - Ernest H Choy
- Institute of Infection & Immunity, Cardiff University School of Medicine, Tenovus Building, Heath Park Campus, Cardiff CF14 4XN, UK
| | - Steve Kanters
- Precision Xtract, 1505 West 2nd Avenue, Suite 300, Vancouver, BC V6H 3Y4, Canada
| | - Howard Thom
- Bristol Medical School: Population Health Sciences, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
| | - Kunal Gandhi
- Oncology Global Development Unit, Novartis Pharmaceuticals Corporation, One Health Plaza, Building 337, B04.3B, East Hanover, NJ, USA
| | - Luminita Pricop
- Immunology & Dermatology Franchise, Novartis Pharmaceuticals Corporation, One Health Plaza, Building 337, B04.3B, East Hanover, NJ, USA
| | - Steffen M Jugl
- Global Patient Access Immunology & Dermatology, Novartis Pharma AG, Asklepios 8-1.001.11, Postfach, Basel, CH-4001, Switzerland
| |
Collapse
|
16
|
Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. BIOMED RESEARCH INTERNATIONAL 2018; 2018:3140983. [PMID: 29546055 PMCID: PMC5818942 DOI: 10.1155/2018/3140983] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/31/2017] [Revised: 10/30/2017] [Accepted: 01/04/2018] [Indexed: 12/12/2022]
Abstract
Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the world's population. Systemic treatments, including methotrexate and cyclosporin, are associated with potential hepatotoxicity, due to either direct liver damage or immunosuppression or both immunomediated and a direct liver injury; therefore, treatment of patients with psoriasis poses a therapeutic challenge. The aim of this minireview is to help clinicians in the management of psoriatic patients who develop signs of liver dysfunction. To find relevant articles, a comprehensive search was performed on PubMed, EMBASE, and Cochrane with appropriate combinations of the following keywords being considered: viral hepatitis, nonalcoholic fatty liver disease, psoriasis, hepatotoxicity, drug toxicity, cholestasis, and autoimmune liver diseases.
Collapse
Affiliation(s)
- Marco Fiore
- Department of Anaesthesiological, Surgical and Emergency Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy
| | - Sebastiano Leone
- Department of Medicine, Division of Infectious Diseases, “San Giuseppe Moscati” Hospital, Avellino, Italy
| | - Alberto Enrico Maraolo
- Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy
| | - Emilio Berti
- Department of Pathophysiology and Transplantation, Dermatology Unit, IRCCS Ca' Granda, University of Milan, Milan, Italy
| | - Giovanni Damiani
- Department of Pathophysiology and Transplantation, Dermatology Unit, IRCCS Ca' Granda, University of Milan, Milan, Italy
- Study Center of Young Dermatologists Italian Network (YDIN), Bergamo, Italy
| |
Collapse
|
17
|
Kunimi Y, Koga M, Ishibashi T, Tanaka Y, Yamamoto T, Imafuku S. Case of psoriatic arthritis mutilans whose finger dysfunction was successfully ameliorated by surgical intervention during infliximab treatment. J Dermatol 2018; 45:e61-e62. [PMID: 29369393 DOI: 10.1111/1346-8138.14234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Yuka Kunimi
- Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Monji Koga
- Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Takuya Ishibashi
- Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Yoshitsugu Tanaka
- Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Takuaki Yamamoto
- Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Shinichi Imafuku
- Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| |
Collapse
|
18
|
Ryser C, Ciurea A. [Therapy of Psoriasis Arthritis Taking into Account New Treatment Options]. PRAXIS 2018; 107:1147-1153. [PMID: 30326810 DOI: 10.1024/1661-8157/a003090] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Therapy of Psoriasis Arthritis Taking into Account New Treatment Options Abstract. Psoriatic arthritis occurs in about 20-30 % of patients with psoriasis. The disease is heterogeneous and can involve a variety of the distinct anatomical sites. The choice of medication depends on the type and the severity of clinical features. The recommendations of EULAR and GRAPPA serve as a guide for the choice of medication, which is used in sequential treatment steps. This is presented in our review in usable, simplified terms. Potential comorbidities leading to contraindication for certain treatments are considered. We present new and highly effective treatments, based on the pathogenesis of psoriasis and psoriatic arthritis, targeting the IL-23/IL-17 pathway.
Collapse
Affiliation(s)
| | - Adrian Ciurea
- 1 Klinik für Rheumatologie, Universitätsspital Zürich
| |
Collapse
|
19
|
Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ. Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity. J Rheumatol 2017; 45:78-82. [PMID: 28966209 DOI: 10.3899/jrheum.161567] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/19/2017] [Indexed: 02/08/2023]
Abstract
OBJECTIVE Rebound may occur in patients with psoriatic arthritis (PsA) who discontinue TNF inhibitor (TNFi) therapy in low disease activity (LDA). METHODS Using physician and patient reports, we quantified rebound following TNFi discontinuation [defined as Clinical Disease Activity Index (CDAI) score > 10 or TNFi restart] and time to rebound in adults with PsA in LDA (CDAI score ≤ 10) at TNFi discontinuation. RESULTS Rebound occurred in 73% (69/94) of patients soon after discontinuation (median time to rebound 8.0 mos, 95% CI 6.0-12.0). CONCLUSION Rebound occurred frequently in patients with PsA after TNFi discontinuation. TNFi discontinuation after achieving LDA should be carefully considered.
Collapse
Affiliation(s)
- Leslie R Harrold
- From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA. .,L.R. Harrold, MD, MPH, Corrona LLC, and Department of Medicine, University of Massachusetts Medical School; B.S. Stolshek, PharmD, Amgen Inc.; S. Rebello, MPH, Corrona LLC; D.H. Collier, MD, Amgen Inc.; A. Mutebi, PhD, Amgen Inc.; S.W. Wade, MPH, Wade Outcomes Research and Consulting; W. Malley, MS, Corrona LLC, and New York University School of Medicine; J.D. Greenberg, MD, MPH, Corrona LLC; C.J. Etzel, PhD, Corrona LLC, and Department of Epidemiology, University of Texas, MD Anderson Cancer Center.
| | - Bradley S Stolshek
- From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.,L.R. Harrold, MD, MPH, Corrona LLC, and Department of Medicine, University of Massachusetts Medical School; B.S. Stolshek, PharmD, Amgen Inc.; S. Rebello, MPH, Corrona LLC; D.H. Collier, MD, Amgen Inc.; A. Mutebi, PhD, Amgen Inc.; S.W. Wade, MPH, Wade Outcomes Research and Consulting; W. Malley, MS, Corrona LLC, and New York University School of Medicine; J.D. Greenberg, MD, MPH, Corrona LLC; C.J. Etzel, PhD, Corrona LLC, and Department of Epidemiology, University of Texas, MD Anderson Cancer Center
| | - Sabrina Rebello
- From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.,L.R. Harrold, MD, MPH, Corrona LLC, and Department of Medicine, University of Massachusetts Medical School; B.S. Stolshek, PharmD, Amgen Inc.; S. Rebello, MPH, Corrona LLC; D.H. Collier, MD, Amgen Inc.; A. Mutebi, PhD, Amgen Inc.; S.W. Wade, MPH, Wade Outcomes Research and Consulting; W. Malley, MS, Corrona LLC, and New York University School of Medicine; J.D. Greenberg, MD, MPH, Corrona LLC; C.J. Etzel, PhD, Corrona LLC, and Department of Epidemiology, University of Texas, MD Anderson Cancer Center
| | - David H Collier
- From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.,L.R. Harrold, MD, MPH, Corrona LLC, and Department of Medicine, University of Massachusetts Medical School; B.S. Stolshek, PharmD, Amgen Inc.; S. Rebello, MPH, Corrona LLC; D.H. Collier, MD, Amgen Inc.; A. Mutebi, PhD, Amgen Inc.; S.W. Wade, MPH, Wade Outcomes Research and Consulting; W. Malley, MS, Corrona LLC, and New York University School of Medicine; J.D. Greenberg, MD, MPH, Corrona LLC; C.J. Etzel, PhD, Corrona LLC, and Department of Epidemiology, University of Texas, MD Anderson Cancer Center
| | - Alex Mutebi
- From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.,L.R. Harrold, MD, MPH, Corrona LLC, and Department of Medicine, University of Massachusetts Medical School; B.S. Stolshek, PharmD, Amgen Inc.; S. Rebello, MPH, Corrona LLC; D.H. Collier, MD, Amgen Inc.; A. Mutebi, PhD, Amgen Inc.; S.W. Wade, MPH, Wade Outcomes Research and Consulting; W. Malley, MS, Corrona LLC, and New York University School of Medicine; J.D. Greenberg, MD, MPH, Corrona LLC; C.J. Etzel, PhD, Corrona LLC, and Department of Epidemiology, University of Texas, MD Anderson Cancer Center
| | - Sally W Wade
- From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.,L.R. Harrold, MD, MPH, Corrona LLC, and Department of Medicine, University of Massachusetts Medical School; B.S. Stolshek, PharmD, Amgen Inc.; S. Rebello, MPH, Corrona LLC; D.H. Collier, MD, Amgen Inc.; A. Mutebi, PhD, Amgen Inc.; S.W. Wade, MPH, Wade Outcomes Research and Consulting; W. Malley, MS, Corrona LLC, and New York University School of Medicine; J.D. Greenberg, MD, MPH, Corrona LLC; C.J. Etzel, PhD, Corrona LLC, and Department of Epidemiology, University of Texas, MD Anderson Cancer Center
| | - Wendi Malley
- From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.,L.R. Harrold, MD, MPH, Corrona LLC, and Department of Medicine, University of Massachusetts Medical School; B.S. Stolshek, PharmD, Amgen Inc.; S. Rebello, MPH, Corrona LLC; D.H. Collier, MD, Amgen Inc.; A. Mutebi, PhD, Amgen Inc.; S.W. Wade, MPH, Wade Outcomes Research and Consulting; W. Malley, MS, Corrona LLC, and New York University School of Medicine; J.D. Greenberg, MD, MPH, Corrona LLC; C.J. Etzel, PhD, Corrona LLC, and Department of Epidemiology, University of Texas, MD Anderson Cancer Center
| | - Jeffrey D Greenberg
- From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.,L.R. Harrold, MD, MPH, Corrona LLC, and Department of Medicine, University of Massachusetts Medical School; B.S. Stolshek, PharmD, Amgen Inc.; S. Rebello, MPH, Corrona LLC; D.H. Collier, MD, Amgen Inc.; A. Mutebi, PhD, Amgen Inc.; S.W. Wade, MPH, Wade Outcomes Research and Consulting; W. Malley, MS, Corrona LLC, and New York University School of Medicine; J.D. Greenberg, MD, MPH, Corrona LLC; C.J. Etzel, PhD, Corrona LLC, and Department of Epidemiology, University of Texas, MD Anderson Cancer Center
| | - Carol J Etzel
- From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.,L.R. Harrold, MD, MPH, Corrona LLC, and Department of Medicine, University of Massachusetts Medical School; B.S. Stolshek, PharmD, Amgen Inc.; S. Rebello, MPH, Corrona LLC; D.H. Collier, MD, Amgen Inc.; A. Mutebi, PhD, Amgen Inc.; S.W. Wade, MPH, Wade Outcomes Research and Consulting; W. Malley, MS, Corrona LLC, and New York University School of Medicine; J.D. Greenberg, MD, MPH, Corrona LLC; C.J. Etzel, PhD, Corrona LLC, and Department of Epidemiology, University of Texas, MD Anderson Cancer Center
| |
Collapse
|
20
|
Patel NU, Vera NC, Shealy ER, Wetzel M, Feldman SR. A Review of the Use of Secukinumab for Psoriatic Arthritis. Rheumatol Ther 2017; 4:233-246. [PMID: 28849401 PMCID: PMC5696288 DOI: 10.1007/s40744-017-0076-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Indexed: 12/21/2022] Open
Abstract
Psoriatic arthritis (PsA) is a chronic, seronegative spondyloarthropathy associated with psoriasis (PsO). Treatment options range from non-pharmacologic measures to NSAIDS, DMARDs, and biologics, depending on patient presentation. Secukinumab (Cosentyx©) is a new biologic treatment option that was approved for use in treating adult patients with PsA in October 2016. Our paper explores the clinical trial evidence available for secukinumab to examine its safety and efficacy as a therapeutic agent for the treatment of PsA. While indirect comparisons of indicate that secukinumab is as effective as other treatment options, further studies directly comparing available treatments will be necessary to establish its place in treatment guidelines. As these and other trials are conducted, the evidence produced will further elucidate the clinical potential of secukinumab as a treatment option for patients with rheumatologic disease.
Collapse
Affiliation(s)
- Nupur U Patel
- Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA.
| | - Nora C Vera
- Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Emily Rose Shealy
- Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Margaret Wetzel
- Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Steven R Feldman
- Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
- Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA
- Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
| |
Collapse
|
21
|
Abstract
PURPOSE OF REVIEW Incorporation of the patients' perspective in clinical research is critical to ensure that outcomes measured reflect those, which matter most to patients. This review summarizes recent efforts to include the patients' perspective in the development of outcome measures and the importance of encouraging patient participation in decision-making and self-management. RECENT FINDINGS Since the inclusion of fatigue as a patient-endorsed core outcome measure in rheumatoid arthritis (RA) trials, OMERACT has been instrumental in advocating for patient involvement in the development of core domains and instruments; current endeavors include cultivating an understanding of remission through the eyes of patients and gaining a sense of how to measure features of pain and 'stiffness' deemed as important to patients. The concept of remission was further explored in RA patients, highlighting a common goal of returning to normality; additionally, various tools have been developed to assess for unmet needs in rheumatology patients. Advances have also been made in the development and revision of patient-centered core measures in rheumatologic diagnoses outside of RA. SUMMARY Incorporating the patients' perspective is now considered an essential feature in outcomes research. Future research should focus on how best to involve patients in specific research activities.
Collapse
|
22
|
Tsuruta N, Imafuku S, Narisawa Y. Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J Dermatol 2017; 44:1349-1352. [DOI: 10.1111/1346-8138.13968] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Accepted: 06/09/2017] [Indexed: 11/29/2022]
Affiliation(s)
- Noriko Tsuruta
- Department of Dermatology; Fukuoka University Faculty of Medicine; Fukuoka Japan
- Division of Dermatology; Department of Internal Medicine; Faculty of Medicine; Saga University; Saga Japan
| | - Shinichi Imafuku
- Department of Dermatology; Fukuoka University Faculty of Medicine; Fukuoka Japan
| | - Yutaka Narisawa
- Division of Dermatology; Department of Internal Medicine; Faculty of Medicine; Saga University; Saga Japan
| |
Collapse
|
23
|
[Psoriatic arthritis : Current therapeutic standards]. Z Rheumatol 2017; 76:495-503. [PMID: 28664281 DOI: 10.1007/s00393-017-0334-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Psoriatic arthritis (PsA) is a heterogeneous immune-mediated disease that usually involves the skin and joints but can also affect the entheses, spine and other extra-articular structures. Furthermore, it can be coupled with associated comorbidities. The selection of a patient-oriented and effective therapy is based on the extent of various manifestations of the disease as well as further influencing factors. Various recommendations for selection and control are available for deciding on a suitable treatment. The recommendations of the European League Against Rheumatism (EULAR) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) are most frequently used and are internationally acknowledged. Both recommendations were updated in 2016. German treatment recommendations are currently lacking. In analogy to the treat-to-target strategy in the treatment of rheumatoid arthritis, minimal disease activity should at least be achieved with the therapeutic intervention used if remission as the therapeutic target cannot be reached. New treatment options, which target different molecules, provide possibilities for a more differentiated therapy for improvement in the treatment of PsA patients.
Collapse
|
24
|
[Tight control of inflammatory activity in the treatment of early psoriatic arthritis : A reasonable therapy strategy for improvement of patient care?]. Z Rheumatol 2017; 75:1032-1034. [PMID: 27844154 DOI: 10.1007/s00393-016-0230-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
25
|
Helliwell PS, Gladman DD, Gottlieb AB. Prologue: 2016 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2017; 44:658-660. [DOI: 10.3899/jrheum.170139] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Miami, Florida, USA, and attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patient groups. As in previous years, GRAPPA members held a symposium for trainees to discuss their research in psoriatic disease with experts in the field. A strategic planning session was convened by the Steering Committee this year to review the work of GRAPPA since its inception in 2003. Other subjects featured during the annual meeting included a partnership with KPMG LLP (UK) to conduct interviews at research centers worldwide to analyze the process of care in psoriasis and psoriatic arthritis (PsA); a discussion of the effects of interleukin 17–related pathways on the skin and joints in psoriasis and PsA; summaries of recently published treatment recommendations and related guides; 4 separate discussions of psoriasis patient examinations; updates from working groups in the Outcome Measures in Rheumatology and the International Dermatology Outcome Measures; a discussion of patient centricity from GRAPPA’s patient research partners; and an update of research and educational projects from GRAPPA. In this prologue, we introduce the papers that summarize that meeting.
Collapse
|
26
|
Abstract
PURPOSE OF REVIEW Incorporation of the patients' perspective in clinical research is critical to ensure that outcomes measured reflect those, which matter most to patients. This review summarizes recent efforts to include the patients' perspective in the development of outcome measures and the importance of encouraging patient participation in decision-making and self-management. RECENT FINDINGS Since the inclusion of fatigue as a patient-endorsed core outcome measure in rheumatoid arthritis (RA) trials, OMERACT has been instrumental in advocating for patient involvement in the development of core domains and instruments; current endeavors include cultivating an understanding of remission through the eyes of patients and gaining a sense of how to measure features of pain and 'stiffness' deemed as important to patients. The concept of remission was further explored in RA patients, highlighting a common goal of returning to normality; additionally, various tools have been developed to assess for unmet needs in rheumatology patients. Advances have also been made in the development and revision of patient-centered core measures in rheumatologic diagnoses outside of RA. SUMMARY Incorporating the patients' perspective is now considered an essential feature in outcomes research. Future research should focus on how best to involve patients in specific research activities.
Collapse
|
27
|
Burden-Teh E, Thomas KS, Rangaraj S, Murphy R. Interviews with paediatric rheumatologists about psoriasis and psoriatic arthritis in children: how can specialties learn from each other? Br J Dermatol 2016; 177:316-318. [PMID: 27680897 DOI: 10.1111/bjd.15090] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- E Burden-Teh
- Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, NG7 2RD, U.K
| | - K S Thomas
- Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, NG7 2RD, U.K
| | - S Rangaraj
- Department of Paediatric and Adolescent Rheumatology, Nottingham Children's Hospital, Nottingham, U.K
| | - R Murphy
- Department of Dermatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, U.K
| |
Collapse
|